Article
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
Rating:
0.0
Views:
56
Likes:
1
Library:
1
- The U.S. FDA has informed UCB via letter that the Agency was unable to complete review of the BLA for bimekizumab by the PDUFA date and is deferring action on the application
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value